Late this spring, a once-daily oral medication for gout posted strong Phase 3 results that are still making their way through the news cycle. In the REDUCE 2 study of 811 patients, 69.2% of those on the 75 mg dose reached a serum urate below 6 mg/dL after six months, versus 56.6% on the 50 mg dose and 8.1% on placebo. Earlier Phase 2 data also showed tophi — the urate crystal deposits under the skin — completely resolving in 43% of hard-to-treat patients at 12 months, rising to 57% when combined with allopurinol. The developer of the drug, known by the code AR882, has said its global rights were acquired by the Swedish pharmaceutical company Sobi.
Headlines about new gout drugs understandably grab attention — the disease is common, painful, and for a subset of patients, poorly controlled. But for the person managing gout day to day, the practical question is different: does better treatment mean diet stops mattering? The short answer, based on how the condition actually works, is no. This article explains what the new data means, where medication and diet each do their work, and why a food database is still useful even in an era of better drugs.
What Urate-Lowering Therapy Actually Does
Medication and diet approach uric acid from different directions. Urate-lowering therapy — whether it is a xanthine oxidase inhibitor like allopurinol or febuxostat, or a uricosuric agent that increases urinary excretion, as AR882 appears to be — works on the body's production and elimination machinery. Its job is to keep serum urate below the crystallization threshold, typically under 6 mg/dL (or under 5 mg/dL in people with tophi), so that existing crystals dissolve and new ones stop forming. The Phase 3 data suggest this new agent is effective at that job for a majority of the patients studied.
Diet works on the input side. Food provides a portion of the body's uric acid load — the purines you eat are metabolized to urate — and dietary patterns also influence urate through weight, insulin resistance, and kidney function. The ACR 2020 guideline treats diet as a component of management, not a replacement for therapy in people who need it, and not something that becomes irrelevant once therapy starts. The two operate in parallel.
Why "On Medication" Does Not Mean "Anything Goes"
Several lines of evidence explain why diet keeps a role even with effective urate-lowering therapy:
- Flare triggers are not all urate-driven. Alcohol, dehydration, and high-purine feasts can precipitate flares even when serum urate is near target, because rapid urate fluctuations and local joint conditions matter. A person whose urate is controlled still has an interest in avoiding the classic triggers.
- Weight and metabolic health. Obesity, insulin resistance, and metabolic syndrome are tightly linked to gout. Diet is the main lever for these, and improving them may reduce how much medication a person needs over time — a decision that belongs to the treating clinician.
- Not everyone tolerates or stays on therapy. Medication adherence in gout is historically poor, and side effects or cost push some people off treatment. For those gaps, diet is the available buffer.
- Tophi and crystal burden take time. Even with excellent urate control, dissolving years of crystal burden takes months. Keeping the input side low during that window is protective.
None of this is an argument against the new drug or against urate-lowering therapy in general. It is a statement about the division of labor: therapy controls the baseline, diet controls the input and the triggers. They are complements, and the patients who do best tend to use both.
What a Food Database Still Offers
If diet remains part of the picture, then knowing what is actually in your food remains part of the toolkit. That is where a purine database earns its keep. A person on urate-lowering therapy who wants to reduce flare risk still benefits from knowing that shrimp, sardines, and organ meats sit at the high end of the purine scale, that beer adds purines on top of alcohol, and that sugar-sweetened drinks carry a fructose load that the ACR guideline flags. The FoodCanEat database lists more than 1,400 foods with purine and fructose values from the USDA/ODS-NIH release and peer-reviewed literature — search an item to see exactly where it lands before you plan a meal.
The database is not a substitute for treatment decisions. What it does is remove guesswork from the food side. When a new drug headline appears, the food side does not change: the same purine values, the same fructose numbers, the same portion logic. That stability is useful.
How to Think About Gout Management in 2026
If you take one idea from this article, it is that gout management has two dials. One dial is treatment, which is improving — new agents, better tolerability, and more attention to target serum urate. The other dial is input: food, drink, hydration, weight. Turning the first dial down does not make the second dial disappear; it makes the second dial matter slightly less at the margins, but it still turns.
There is also a timing argument that rarely gets mentioned. When a person begins urate-lowering therapy, the risk of flares can rise in the early months as crystals dissolve and shift, which is why guidelines describe a flare-prevention window at the start of treatment. Keeping the food side clean during that window is not redundant; it is one of the few variables a patient fully controls while the medication does its longer work. The same logic applies to the years after: with serum urate in range, a single weekend of heavy beer and shellfish can still test the system. Diet is the buffer that stays with you between appointments.
For most people, the practical plan is unchanged: follow your clinician's guidance on medication, keep alcohol and sugary drinks modest, choose lower-purine foods more often, stay hydrated, and use the food data available to you. If a new medication becomes available in the future, it will be your clinician's call whether it fits your situation. Until then, the food choices you can control today are still worth controlling.
Frequently Asked Questions
If I take gout medication, can I eat whatever I want?
Not exactly. Medication keeps your baseline urate lower, which reduces — but does not eliminate — the effect of dietary spikes. Alcohol, dehydration, and very high-purine meals can still trigger flares in some people even on therapy. Most clinicians advise keeping sensible food habits while on treatment rather than treating medication as a free pass.
Will the new drug replace allopurinol?
That is not something anyone can conclude from Phase 3 data alone, and prescribing decisions rest with clinicians. The study showed the new agent working well in the trial population, including tophi resolution in a meaningful share of patients. Whether it changes first-line practice depends on regulatory review, real-world data, cost, and tolerability comparisons — all of which take time.
Is diet still worth tracking if my urate is already under 6 mg/dL?
For most people, yes, with a lighter touch. With urate at target, the goal shifts from lowering baseline to avoiding triggers and supporting weight and metabolic health. Tracking the highest-purine items and alcohol is enough — you do not need to manage every food with the same intensity as during an uncontrolled period.
References: REDUCE 2 Phase 3 results summary (company release, 2026) — clinicaltrials.gov; Phase 2 tophi data as reported in company communications (2025); FitzGerald et al., Arthritis Care Res 2020 (ACR 2020 gout guideline, PMID: 32391934); Dalbeth et al., Ann Rheum Dis 2018 (treat-to-target urate, PMID: 29463518); USDA & ODS-NIH Database for the Purine Content of Foods, Release 2.0 (2025) — ars.usda.gov.